Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

23/09 Earnings release - Q2 2026

More about the company

Market Cap	11.68M 13.57M 10.97M 10.01M 18.81M 1.29B 18.95M 130M 50.58M 655M 50.95M 49.84M 2.17B	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	9.97M 11.59M 9.37M 8.55M 16.06M 1.1B 16.18M 111M 43.18M 559M 43.5M 42.55M 1.85B	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	34.3%	Yield 2024 *	-	Yield 2025	-

14/07	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC	CI
14/07	Celyad Oncology to Raise Funds via Private Placement	MT
15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
03/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/09/25	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
30/09/25	Celyad Oncology announces research facility divestiture	RE
29/09/25	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
26/09/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/08/25	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/07/25	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/07/25	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/06/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
25/06/25	Celyad Oncology Announces Strategic Review	CI

01/03/22	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
12/01/22	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/08/21	Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
27/03/21	Celyad Oncology : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
09/12/20	Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

29/07	Celyad Oncology : Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)	PU
14/07	Celyad Oncology : Announces €500,000 Private Placement	PU
21/05	Celyad Oncology : AGM Minutes - informal translation EN	PU
03/04	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
30/09/25	Celyad Oncology : Announces Research Facility Divestiture	PU

29/07	Celyad Oncology : Publication d’une notification de transparence reçue de Tolefi SA (Article 14§1 de la Loi du 2 Mai 2007)
18/07	Rustige start cijferseizoen in Brussel
14/07	Celyad kondigt private plaatsing van 500.000 euro aan
21/05	Celyad Oncology : AGO Procès Verbal - version FR
17/04	Celyad Oncology : Rapport Annuel 2025 FR

Celyad SA Stock Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation : Celyad SA

Latest news : Celyad SA

Analysts' recommendations : Celyad SA

Press Releases : Celyad SA

News in other languages : Celyad SA

Quotes and Performance

Managers and Directors : Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Serge Goblet BRD	Director/Board Member	-	01/01/2008
Hilde Windels CHM	Chairman	61	23/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	13.56M
LONZA GROUP AG	-1.23%	-1.91%	+0.98%	+17.94%	50.47B
REVOLUTION MEDICINES, INC.	-1.11%	-2.84%	+420.04%	+505.15%	44.56B
IQVIA HOLDINGS INC.	-0.21%	+0.37%	+36.88%	+17.32%	43.08B
BEONE MEDICINES AG	-1.95%	-3.33%	+8.29%	+73.25%	41.7B
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	33.21B
MEDPACE HOLDINGS, INC.	-1.11%	-4.20%	+25.49%	+119.78%	16.77B
ASCENDIS PHARMA A/S	+6.10%	+4.40%	-	-	16.28B
EUROFINS SCIENTIFIC SE	+0.25%	-0.98%	+11.91%	+27.62%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.12%	-3.46%	+76.50%	+39.37%	13.92B
Average	-2.66%	-1.79%	+74.80%	+105.91%	30.51B
Weighted average by Cap.	-0.60%	-1.57%	+88.95%	+122.85%

	2024	2025
Net sales	186K 216K 175K 159K 299K 20.55M 302K 2.07M 805K 10.42M 811K 793K 34.51M	21K 24.39K 19.72K 18K 33.81K 2.32M 34.06K 234K 90.91K 1.18M 91.58K 89.59K 3.9M
Net income	-5.82M -6.76M -5.47M -4.99M -9.38M -644M -9.44M -64.8M -25.21M -326M -25.4M -24.85M -1.08B	830K 964K 779K 711K 1.34M 91.72M 1.35M 9.23M 3.59M 46.51M 3.62M 3.54M 154M
Net Debt	-3.3M -3.83M -3.09M -2.82M -5.31M -364M -5.34M -36.66M -14.26M -185M -14.37M -14.06M -611M	-1.71M -1.98M -1.6M -1.46M -2.75M -189M -2.77M -19M -7.39M -95.71M -7.45M -7.29M -317M